Bristol Myers Squibb and Hengrui Pharma sign major licencing deal
The agreement between the pharmaceutical firms includes collaboration and licence agreements on early-stage programmes for oncology, hematology, immunology and innovative assets; BMS Is paying an upfront payment of $600m.
May 12, 2026





.jpg&h=171&w=304&q=75&v=c677659a95&c=1)


.jpg&h=171&w=304&q=75&v=c677659a95&c=1)
